larotrectinib
bayer
['larotrectinib', 'solid tumor', 'kvi,(-kviii),(-rockville)', 'vitrakvi', '$bayry']
$bayry latest vitrakvi (larotrectinib) subgroup analyses at asco 2023 showcase long-term efficacy and safety profile in adult and pediatric patients with ntrk gene fusion cancer, across solid tumors - 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities